NCT04887259 - Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 12, 2021

Primary Completion Date

September 6, 2023

Study Completion Date

September 6, 2023

Conditions

Chronic Lymphocytic LeukemiaMultiple MyelomaAcute Myeloid Leukemia

Interventions

BIOLOGICAL

LAVA-051

In part 1 and part 2, LAVA-051 will be administered via intravenous (IV) infusion

BIOLOGICAL

Interleukin 2

In Part 1 and Part 2, a low dose of interleukin 2 will be given via subcutaneous injection with LAVA-051 in a selected group of patients

Trial Locations (14)

NYU Langone Health, New York

Cima University of Navarra, Madrid

Levine Cancer Institute, Atrium Health, Charlotte

Emory Winship Cancer Institute, Atlanta

Clinica Universida de Navarra, Pamplona

Hospital Clinico Universitario de Salamanca, Salamanca

University Hospital of Nantes, Nantes

Cleveland Clinic, Cleveland

CHU Lille, Lille

MD Anderson Cancer Center, Houston

Amsterdam UMC, location VUmc, Amsterdam

Amsterdam UMC, location AMC, Amsterdam

Erasmus MC, Rotterdam

University Hospital Vall d'Hebron, Barcelona